Phase I trial of a multi-epitope-pulsed dendritic cell vac
diagnosed glioblastoma

Cancer Immunology, Immunotherapy

62, 125-135

DOI: 10.1007/s00262-012-1319-0

Citation Report

#	Article	IF	Citations
1	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncology, 2013, 9, 977-990.	1.1	21
2	Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunology, Immunotherapy, 2013, 62, 1499-1509.	2.0	236
4	Immune-Checkpoint Blockade and Active Immunotherapy for Glioma. Cancers, 2013, 5, 1379-1412.	1.7	33
5	Industry progress report on neuro-oncology: Biotech update 2013. Journal of Neuro-Oncology, 2013, 115, 311-316.	1.4	6
6	The expression and clinical significance of melanoma-associated antigen-A1, -A3 and -A11 in glioma. Oncology Letters, 2013, 6, 55-62.	0.8	19
7	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nature Reviews Clinical Oncology, 2013, 10, 14-26.	12.5	281
8	Vaccine strategies for glioblastoma: progress and future directions. Immunotherapy, 2013, 5, 155-167.	1.0	33
9	Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treatment Reviews, 2013, 39, 891-907.	3.4	64
10	Treatment Options in Newly Diagnosed Glioblastoma. Current Treatment Options in Neurology, 2013, 15, 281-288.	0.7	10
11	Clinical trials in cellular immunotherapy for brain/CNS tumors. Expert Review of Neurotherapeutics, 2013, 13, 405-424.	1.4	18
12	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Review of Vaccines, 2013, 12, 597-615.	2.0	60
13	Vaccine-based immunotherapy for glioblastoma. CNS Oncology, 2013, 2, 331-349.	1.2	11
14	Tracking and evaluation of dendritic cell migration by cellular magnetic resonance imaging. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2013, 5, 469-483.	3.3	45
15	Generation of more effective cancer vaccines. Human Vaccines and Immunotherapeutics, 2013, 9, 2543-2547.	1.4	11
16	Trial watch. OncoImmunology, 2013, 2, e25771.	2.1	150
17	Dendritic Cell Vaccine for Recurrent High-Grade Gliomas in Pediatric and Adult Subjects. Neurosurgery, 2013, 73, 863-867.	0.6	18
18	Dendritic Cell Vaccination in Pediatric Gliomas: Lessons Learnt and Future Perspectives. Frontiers in Pediatrics, 2013, 1, 12.	0.9	9
19	Peptide-Pulsed Dendritic Cells Have Superior Ability to Induce Immune-Mediated Tissue Destruction Compared to Peptide with Adjuvant. PLoS ONE, 2014, 9, e92380.	1.1	12

#	Article	IF	Citations
20	Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response. ImmunoTargets and Therapy, 2014, 3, 55.	2.7	5
21	The Value of EGFRvIII as the Target for Glioma Vaccines. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 42-50.	1.8	5
22	Recent advances in immunotherapy for non-small-cell lung cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 352-357.	1.4	16
23	Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. Expert Review of Vaccines, 2014, 13, 87-116.	2.0	3
24	DCVaxÂ®-Lâ€"Developed by Northwest Biotherapeutics. Human Vaccines and Immunotherapeutics, 2014, 10, 3139-3145.	1.4	53
25	The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy. Cancers, 2014, 6, 1953-1985.	1.7	62
26	HER2/neu: an increasingly important therapeutic target. Part 3: clinical applications and investigations. Clinical Investigation, 2014, 4, 791-823.	0.0	1
27	HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium. Clinical Investigation, 2014, 4, 649-671.	0.0	6
28	Current Vaccine Trials in Glioblastoma: A Review. Journal of Immunology Research, 2014, 2014, 1-10.	0.9	65
29	Dendritic cell vaccination for glioblastoma multiforme: Clinical experience and future directions. , 2014, , .		0
30	The role of cancer stem cells in glioblastoma. Neurosurgical Focus, 2014, 37, E6.	1.0	97
31	Eradication of Growth of HER2-Positive Ovarian Cancer With Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate in Mouse Xenograft Model. International Journal of Gynecological Cancer, 2014, 24, 1158-1164.	1.2	27
32	Glioma-Associated Antigen HEATR1 Induces Functional Cytotoxic T Lymphocytes in Patients with Glioma. Journal of Immunology Research, 2014, 2014, 1-12.	0.9	22
33	A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy. Journal of Immunology Research, 2014, 2014, 1-16.	0.9	24
34	Adoptive Immunotherapy for Cancer or Viruses. Annual Review of Immunology, 2014, 32, 189-225.	9.5	240
35	Dendritic cells and cancer immunotherapy. Current Opinion in Immunology, 2014, 27, 26-32.	2.4	108
36	Dendritic Cell-Based Vaccine for the Treatment of Malignant Glioma: A Systematic Review. Cancer Investigation, 2014, 32, 451-457.	0.6	38
37	Immunotherapy for Brain Cancer: Recent Progress and Future Promise. Clinical Cancer Research, 2014, 20, 3651-3659.	3.2	92

#	Article	IF	Citations
38	Recognizing and Correcting Failures in Glioblastoma Treatment. Cancer Investigation, 2014, 32, 299-302.	0.6	5
39	Immunotherapy advances for glioblastoma. Neuro-Oncology, 2014, 16, 1441-1458.	0.6	164
40	Vaccine therapies for patients with glioblastoma. Journal of Neuro-Oncology, 2014, 119, 531-546.	1.4	32
41	Dendritic cell immunotherapy for glioblastoma. Expert Review of Anticancer Therapy, 2014, 14, 761-763.	1.1	5
42	Advances in kinase targeting: current clinical use and clinical trials. Trends in Pharmacological Sciences, 2014, 35, 604-620.	4.0	178
43	Stem cell in alternative treatments for brain tumors: potential for gene delivery. Molecular and Cellular Therapies, 2014, 2, 24.	0.2	6
44	Intrinsically de-sialylated CD103+ CD8 T cells mediate beneficial anti-glioma immune responses. Cancer Immunology, Immunotherapy, 2014, 63, 911-924.	2.0	31
45	Cytokine responsiveness of CD8+ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. , 2014, 2, 10.		29
46	Evolution of Malignant Glioma Treatment. Neurosurgery, 2014, 61, 74-83.	0.6	18
47	Immunotherapy of Brain Tumors. Progress in Tumor Research, 2015, 42, 11-21.	0.1	7
48	Development of a Method for Generation of Immune Competent Dendritic Cells in a Large Scale by Using Human Peripheral Blood Monocytes with Gene Modifications. Major Histocompatibility Complex, 2015, 22, 37-43.	0.2	0
49	Immunotherapy for glioblastoma. Current Opinion in Neurology, 2015, 28, 639-646.	1.8	25
50	Stem Cell Therapy for Brain Tumors. International Journal of Translational Science, 2015, 2015, 67-106.	0.2	1
51	Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. Viruses, 2015, 7, 6009-6042.	1.5	67
52	Brain Tumor Immunotherapy: What have We Learned so Far?. Frontiers in Oncology, 2015, 5, 98.	1.3	28
53	CD133 Expression Is Not Synonymous to Immunoreactivity for AC133 and Fluctuates throughout the Cell Cycle in Glioma Stem-Like Cells. PLoS ONE, 2015, 10, e0130519.	1.1	31
54	Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. BioMed Research International, 2015, 2015, 1-12.	0.9	29
55	Neurosurgery concepts: Key perspectives on dendritic cell vaccines, metastatic tumor treatment, and radiosurgery. , 2015, 6, 6.		1

#	Article	IF	Citations
56	Immunotherapeutic Advancements for Glioblastoma. Frontiers in Oncology, 2015, 5, 12.	1.3	37
57	Advances in the treatment of newly diagnosed glioblastoma. BMC Medicine, 2015, 13, 293.	2.3	36
58	Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. Journal of Neuro-Oncology, 2015, 121, 319-329.	1.4	52
59	Enhanced immunosuppression by therapyâ€exposed glioblastoma multiforme tumor cells. International Journal of Cancer, 2015, 136, 2566-2578.	2.3	38
60	Active dendritic cell immunotherapy for glioblastoma: Current status and challenges. British Journal of Neurosurgery, 2015, 29, 197-205.	0.4	21
61	Biomarkers for glioma immunotherapy: the next generation. Journal of Neuro-Oncology, 2015, 123, 359-372.	1.4	23
62	Glioblastoma antigen discoveryâ€"foundations for immunotherapy. Journal of Neuro-Oncology, 2015, 123, 347-358.	1.4	7
63	Personalized Medicine for Gliomas. , 2015, 6, 89.		31
64	Cancer stem cells in glioblastoma. Genes and Development, 2015, 29, 1203-1217.	2.7	1,248
65	Concepts of immunotherapy for glioma. Journal of Neuro-Oncology, 2015, 123, 323-330.	1.4	12
66	Tregs in gliomas - the jury is still out. Neuro-Oncology, 2015, 17, 769-770.	0.6	4
67	Static Image Analysis as New Approach for the Characterization of Tumor Cell Lysate Used in Dendritic Cell Vaccine Preparation. Transfusion Medicine and Hemotherapy, 2015, 42, 122-128.	0.7	2
68	Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. Journal of Neuro-Oncology, 2015, 123, 373-383.	1.4	14
69	Recent news in the glioblastoma research. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2015, 9, 1-12.	0.3	0
70	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. Neuro-Oncology, 2015, 17, vii32-vii40.	0.6	21
71	Vaccination strategies for neuro-oncology: Table 1.. Neuro-Oncology, 2015, 17, vii15-vii25.	0.6	25
72	Brain Cancer: The New Frontiers. , 2015, , 231-246.		0
73	An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. Current Treatment Options in Oncology, 2015, 16, 54.	1.3	44

#	Article	IF	Citations
74	Novel chemotherapeutics and other therapies for treating high-grade glioma. Expert Opinion on Investigational Drugs, 2015, 24, 1361-1379.	1.9	23
75	Overview of current immunotherapeutic strategies for glioma. Immunotherapy, 2015, 7, 1073-1104.	1.0	40
76	Vaccine Therapies in Malignant Glioma. Current Neurology and Neuroscience Reports, 2015, 15, 508.	2.0	21
77	Immunotherapy for Malignant Gliomas. Cancer Treatment and Research, 2015, 163, 143-158.	0.2	11
78	Current Understanding and Treatment of Gliomas. Cancer Treatment and Research, 2015, , .	0.2	11
79	Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment. Immunobiology, 2015, 220, 243-248.	0.8	13
80	CD8 T Cellâ€“Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas. Cancers, 2016, 8, 71.	1.7	8
81	Mitochondrion: A Promising Target for Nanoparticle-Based Vaccine Delivery Systems. Vaccines, 2016, 4, 18.	2.1	9
82	Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System. International Journal of Molecular Sciences, 2016, 17, 2030.	1.8	12
83	Novel vaccines for glioblastoma: clinical update and perspective. Immunotherapy, 2016, 8, 1293-1308.	1.0	23
84	HER2-targeted recombinant protein immuno-caspase-6 effectively induces apoptosis in HER2-overexpressing GBM cells in vitro and in vivo. Oncology Reports, 2016, 36, 2689-2696.	1.2	7
85	Pharmacotherapies for the treatment of glioblastoma â€“ current evidence and perspectives. Expert Opinion on Pharmacotherapy, 2016, 17, 1259-1270.	0.9	24
86	Tumor antigenâ€“specific T cells for immune monitoring of dendritic cellâ€“treated glioblastoma patients. Cytotherapy, 2016, 18, 1146-1161.	0.3	6
87	Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma. Cancer Immunology, Immunotherapy, 2016, 65, 1499-1509.	2.0	52
88	Targeted Therapies for Glioma Stem Cells. , 2016, , 459-471.		0
89	Cellular immunotherapy for malignant gliomas. Expert Opinion on Biological Therapy, 2016, 16, 1265-1275.	1.4	37
90	Perspectives on investigational drugs and immunotherapies for glioblastoma. Expert Opinion on Investigational Drugs, 2016, 25, 1007-1009.	1.9	2
91	Recent advances and future of immunotherapy for glioblastoma. Expert Opinion on Biological Therapy, 2016, 16, 1245-1264.	1.4	57

#	Article	IF	Citations
92	Pulsed Dendritic Cells for the Therapy of Experimental Glioma. Bulletin of Experimental Biology and Medicine, 2016, 161, 792-796.	0.3	1
93	Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. Cancer Immunology Research, 2016, 4, 1007-1015.	1.6	84
94	Immunotherapy of Brain Cancer. Oncology Research and Treatment, 2016, 39, 326-334.	0.8	14
95	Radiobiology of Glioblastoma. Current Clinical Pathology, 2016, , .	0.0	2
96	Evolving Strategies for Therapeutically Targeting Cancer Stem Cells. Advances in Cancer Research, 2016, 131, 159-191.	1.9	47
97	Developing immunotherapeutic strategies to target brain tumors. Expert Review of Anticancer Therapy, 2016, 16, 775-788.	1.1	5
98	Improving vaccine efficacy against malignant glioma. OncoImmunology, 2016, 5, e1196311.	2.1	16
99	The Immune System and Its Contribution to the Radiotherapeutic Response of Glioblastoma. Current Clinical Pathology, 2016, , 155-175.	0.0	0
100	Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. Seminars in Radiation Oncology, 2016, 26, 281-298.	1.0	23
101	Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era. Journal of Clinical Neuroscience, 2016, 24, 105-111.	0.8	35
102	Immunomonitoring in glioma immunotherapy: current status and future perspectives. Journal of Neuro-Oncology, 2016, 127, 1-13.	1.4	20
103	TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination. Cancer Immunology Research, 2016, 4, 412-418.	1.6	64
104	Principles of immunotherapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 163-181.	1.0	12
105	Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells. Seminars in Oncology, 2016, 43, 291-299.	0.8	13
106	Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology, 2016, 5, e1145332.	2.1	13
107	Immunotherapy of Cancer. , 2016, , .		3
108	Dendritic Cell-Based Vaccine for Cancer. , 2016, , 197-220.		0
109	Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma. Cancer Immunology, Immunotherapy, 2016, 65, 127-139.	2.0	18

#	Article	IF	Citations
110	Immunotherapy for cancer in the central nervous system: Current and future directions. OncoImmunology, 2016, 5, e1082027.	2.1	72
111	Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies. Cancer Immunology, Immunotherapy, 2016, 65, 101-109.	2.0	42
112	Current and future strategies for treatment of glioma. Neurosurgical Review, 2017, 40, 1-14.	1.2	416
113	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Seminars in Immunopathology, 2017, 39, 225-239.	2.8	42
114	Functional analysis of KIF20A, a potential immunotherapeutic target for glioma. Journal of Neuro-Oncology, 2017, 132, 63-74.	1.4	48
115	Immunotherapy for High-Grade Gliomas. , 2017, , 177-192.		0
116	Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. Clinical Cancer Research, 2017, 23, 3575-3584.	3.2	78
118	Immune and viral therapies for malignant primary brain tumors. Expert Opinion on Biological Therapy, 2017, 17, 457-474.	1.4	16
119	The Survival Advantage of â€œSupratotalâ€•Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique. Neurosurgery, 2017, 81, 275-288.	0.6	96
120	Targeting the immune system in glioblastoma. Expert Review of Precision Medicine and Drug Development, 2017, 2, 121-131.	0.4	0
121	Dendritic cell based vaccination strategy: an evolving paradigm. Journal of Neuro-Oncology, 2017, 133, 223-235.	1.4	39
122	History and current state of immunotherapy in glioma and brain metastasis. Therapeutic Advances in Medical Oncology, 2017, 9, 347-368.	1.4	59
123	Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nature Reviews Neurology, 2017, 13, 363-374.	4.9	125
124	A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. Journal of Translational Medicine, 2017, 15, 104.	1.8	100
125	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Gliomaâ€“Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. Current Neurology and Neuroscience Reports, 2017, 17, 50.	2.0	10
126	Cellular immunotherapy of cancer: an overview and future directions. Immunotherapy, 2017, 9, 589-606.	1.0	13
127	Glioblastoma targeted therapy: updated approaches from recent biological insights. Annals of Oncology, 2017, 28, 1457-1472.	0.6	314
129	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. Acta Neuropathologica, 2017, 134, 297-316.	3.9	23

#	Article	IF	Citations
130	Tumor Vaccines for Malignant Gliomas. Neurotherapeutics, 2017, 14, 345-357.	2.1	41
131	Single vs. combination immunotherapeutic strategies for glioma. Expert Opinion on Biological Therapy, 2017, 17, 543-554.	1.4	17
132	Immunotherapy for malignant primary brain tumors with ICT-107, a dendritic cell vaccine. Expert Opinion on Orphan Drugs, 2017, 5, 85-89.	0.5	0
133	The Safety of available immunotherapy for the treatment of glioblastoma. Expert Opinion on Drug Safety, 2017, 16, 277-287.	1.0	19
135	Inflammation and Cancer: The Role of Lipid Signaling in the Continuum Between Two Ends of the Tumor Spectrum. , 2017, , 167-193.		1
136	Advances in immunotherapy for the treatment of glioblastoma. Journal of Neuro-Oncology, 2017, 131, 1-9.	1.4	65
137	Immunotherapy approaches in the treatment of malignant brain tumors. Cancer, 2017, 123, 734-750.	2.0	75
138	Dendritic Cell Therapy for Brain Tumors. , 2017, , 301-321.		0
139	Immunotherapy Clinical Trials in Neuro-Oncology. , 2017, , 181-210.		0
140	Peptide-Specific Vaccines. , 2017, , 213-226.		1
141	Advances in Immunotherapy for Glioblastoma Multiforme. Journal of Immunology Research, 2017, 2017, 1-11.	0.9	73
142	Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer. , 2017, 5, 69.		29
143	Advances in the Treatment of Primary Brain Tumors: The Realm of Immunotherapy. , 0, , .		0
144	Immunotherapy for Brain Tumors. Journal of Clinical Oncology, 2017, 35, 2450-2456.	0.8	112
145	On the Concepts and History of Glioblastoma Multiforme - Morphology, Genetics and Epigenetics. Folia Medica, 2018, 60, 48-66.	0.2	45
146	Quo Vadisâ€"Do Immunotherapies Have a Role in Glioblastoma?. Current Treatment Options in Neurology, 2018, 20, 14.	0.7	22
147	Automated generation of immature dendritic cells in a single-use system. Journal of Immunological Methods, 2018, 457, 53-65.	0.6	4
148	Current state of immunotherapy for glioblastoma. Nature Reviews Clinical Oncology, 2018, 15, 422-442.	12.5	873

#	Article	IF	Citations
149	Current state and future prospects of immunotherapy for glioma. Immunotherapy, 2018, 10, 317-339.	1.0	60
150	Immunotherapy of Gliomas. , 2018, , 657-664.		0
151	19F-perfluorocarbon-labeled human peripheral blood mononuclear cells can be detected in vivo using clinical MRI parameters in a therapeutic cell setting. Scientific Reports, 2018, 8, 590.	1.6	42
152	Vaccine Strategies in Gliomas. Current Treatment Options in Neurology, 2018, 20, 11.	0.7	12
153	Vaccination in the immunotherapy of glioblastoma. Human Vaccines and Immunotherapeutics, 2018, 14, 255-268.	1.4	50
154	Advances in immunotherapeutic research for glioma therapy. Journal of Neurology, 2018, 265, 741-756.	1.8	77
155	High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma. Molecular Medicine Reports, 2019, 19, 877-884.	1.1	12
156	Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. Frontiers in Immunology, 2018, 9, 2924.	2.2	171
157	Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives. World Neurosurgery, 2018, 120, 302-315.	0.7	29
158	Promising vaccines for treating glioblastoma. Expert Opinion on Biological Therapy, 2018, 18, 1159-1170.	1.4	8
159	Receptor-Targeted Glial Brain Tumor Therapies. International Journal of Molecular Sciences, 2018, 19, 3326.	1.8	34
160	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. Cancers, 2018, 10, 372.	1.7	67
161	A Critical Overview of Targeted Therapies for Glioblastoma. Frontiers in Oncology, 2018, 8, 419.	1.3	167
162	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. Frontiers in Immunology, 2018, 9, 2265.	2.2	107
163	A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. Trials, 2018, 19, 293.	0.7	27
164	Therapeutic Immunization against Glioblastoma. International Journal of Molecular Sciences, 2018, 19, 2540.	1.8	14
165	Overview of Dendritic Cell Vaccines for Brain Tumors. , 2018, , 681-692.		0
166	High-grade glioma associated immunosuppression does not prevent immune responses induced by therapeutic vaccines in combination with Treg depletion. Cancer Immunology, Immunotherapy, 2018, 67, 1545-1558.	2.0	13

#	Article	IF	Citations
167	Immunotherapy in Glioblastoma. World Neurosurgery, 2018, 116, 518-528.	0.7	31
168	Cell-Based Immunotherapy of Gliomas. Progress in Neurological Surgery, 2018, 32, 90-100.	1.3	7
169	Glioblastoma Treatments: An Account of Recent Industrial Developments. Frontiers in Pharmacology, 2018, 9, 879.	1.6	93
170	Dendritic cell vaccines for high-grade gliomas. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1299-1313.	0.9	42
171	Direct loading of CTL epitopes onto MHC class I complexes on dendritic cell surface in vivo. Biomaterials, 2018, 182, 92-103.	5.7	11
172	Preservation of cell-based immunotherapies for clinical trials. Cytotherapy, 2019, 21, 943-957.	0.3	70
173	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clinical Cancer Research, 2019, 25, 5799-5807.	3.2	166
174	An Anticancer Drug Cocktail of Three Kinase Inhibitors Improved Response to a Dendritic Cellâ€"Based Cancer Vaccine. Cancer Immunology Research, 2019, 7, 1523-1534.	1.6	10
175	A Multi-Element Expression Score Is A Prognostic Factor In Glioblastoma Multiforme . Cancer Management and Research, 2019, Volume 11, 8977-8989.	0.9	6
176	The NFL-TBS.40â€"63 peptide targets and kills glioblastoma stem cells derived from human patients and also targets nanocapsules into these cells. International Journal of Pharmaceutics, 2019, 566, 218-228.	2.6	8
177	Targeted Therapies for the Treatment of Glioblastoma in Adults. Current Oncology Reports, 2019, 21, 61.	1.8	15
178	A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials. Cancers, 2019, 11, 537.	1.7	66
179	Novel approaches for the design, delivery and administration of vaccine technologies. Clinical and Experimental Immunology, 2019, 196, 189-204.	1.1	82
180	The Role of SVZ Stem Cells in Glioblastoma. Cancers, 2019, 11, 448.	1.7	53
181	Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. World Neurosurgery, 2019, 124, 397-409.	0.7	19
182	Clinical Trial Outcomes. JACC: Heart Failure, 2019, 7, 272-273.	1.9	6
183	Sarcosine promotes trafficking of dendritic cells and improves efficacy of anti-tumor dendritic cell vaccines via CXC chemokine family signaling. , 2019, 7, 321.		22
184	Adjuvant therapy and molecular profiling for inoperable gliomas. , 2019, , 193-208.		0

#	Article	IF	Citations
185	Biological intratumoral therapy for the high-grade glioma part II: vector- and cell-based therapies and radioimmunotherapy. CNS Oncology, 2019, 8, CNS40.	1.2	6
186	Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. Frontiers in Immunology, 2018, 9, 3062.	2.2	49
187	Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research. Cancer Investigation, 2019, 37, 1-7.	0.6	6
188	A Bayesian design for phase I cancer therapeutic vaccine trials. Statistics in Medicine, 2019, 38, 1170-1189.	0.8	6
189	Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success. Stem Cells Translational Medicine, 2019, 8, 75-81.	1.6	141
190	Dendritic cells as cancer therapeutics. Seminars in Cell and Developmental Biology, 2019, 86, 77-88.	2.3	50
191	Insights in the immunobiology of glioblastoma. Journal of Molecular Medicine, 2020, 98, 1-10.	1.7	46
192	Insights into new mechanisms and models of cancer stem cell multidrug resistance. Seminars in Cancer Biology, 2020, 60, 166-180.	4.3	188
193	Role of myeloid cells in the immunosuppressive microenvironment in gliomas. Immunobiology, 2020, 225, 151853.	0.8	50
194	Molecular imaging and advanced MRI findings following immunotherapy in patients with brain tumors. Expert Review of Anticancer Therapy, 2020, 20, 9-15.	1.1	10
195	Brain immunology and immunotherapy in brain tumours. Nature Reviews Cancer, 2020, 20, 12-25.	12.8	389
196	Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. Cancer Immunology, Immunotherapy, 2020, 69, 135-145.	2.0	42
197	CAR T-Cell Therapy for CNS Malignancies. , 2020, , 165-198.		0
198	Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment. Frontiers in Immunology, 2020, 11, 582106.	2.2	50
199	Novel Treatment Strategies for Glioblastoma. Cancers, 2020, 12, 2883.	1.7	42
200	Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2020, 150, 269-359.	1.4	8
201	Clinical implication of cellular vaccine in glioma: current advances and future prospects. Journal of Experimental and Clinical Cancer Research, 2020, 39, 257.	3.5	31
202	Nanomedicine Revisited: Next Generation Therapies for Brain Cancer. Advanced Therapeutics, 2020, 3, 2000118.	1.6	14

#	Article	IF	Citations
203	Inflammatory Mediators in Glioma Microenvironment Play a Dual Role in Gliomagenesis and Mesenchymal Stem Cell Homing: Implication for Cellular Therapy. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 443-459.	1.2	51
204	Biomarkers for immunotherapy for treatment of glioblastoma. , 2020, 8, e000348.		33
205	A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. Journal of Clinical Neuroscience, 2020, 74, 187-193.	0.8	35
206	T lymphocyte-targeted immune checkpoint modulation in glioma. , 2020, 8, e000379.		28
207	Tumor-Specific T Cell Activation in Malignant Brain Tumors. Frontiers in Immunology, 2020, 11, 205.	2.2	36
208	Low Fraction Size Re-irradiation for Large Volume Recurrence of Glial Tumours. Pathology and Oncology Research, 2020, 26, 2651-2658.	0.9	2
209	Immunotherapy for glioma: Current management and future application. Cancer Letters, 2020, 476, 1-12.	3.2	351
210	Cholesterol-modified DP7 enhances the effect of individualized cancer immunotherapy based on neoantigens. Biomaterials, 2020, 241, 119852.	5.7	32
211	Immunotherapy for Malignant Glioma: Current Status and Future Directions. Trends in Pharmacological Sciences, 2020, 41, 123-138.	4.0	121
212	Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors. Npj Vaccines, 2020, 5, 5.	2.9	19
213	Drug Conjugates for Targeting Eph Receptors in Glioblastoma. Pharmaceuticals, 2020, 13, 77.	1.7	7
214	A review of glioblastoma immunotherapy. Journal of Neuro-Oncology, 2021, 151, 41-53.	1.4	159
215	Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples. Human Gene Therapy, 2021, 32, 192-202.	1.4	13
216	Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Medical Hypotheses, 2021, 146, 110365.	0.8	24
217	Considerations when treating high-grade pediatric glioma patients with immunotherapy. Expert Review of Neurotherapeutics, 2021, 21, 205-219.	1.4	5
218	Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges. Frontiers in Oncology, 2021, 11, 615704.	1.3	27
219	Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I). Brain Sciences, 2021, 11, 386.	1.1	14
220	Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies. Genes, 2021, 12, 445.	1.0	43

#	Article	IF	Citations
221	Current Immunotherapies for Glioblastoma Multiforme. Frontiers in Immunology, 2020, 11, 603911.	2.2	77
222	Brain Tumor Vaccines. Neurosurgery Clinics of North America, 2021, 32, 225-234.	0.8	4
223	Immunotherapy and radiation for high-grade glioma: a narrative review. Translational Cancer Research, 2021, 10, 2537-2570.	0.4	6
224	Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. Frontiers in Pharmacology, 2021, 12, 680021.	1.6	33
225	Advanced Immunotherapy Approaches for Glioblastoma. Advanced Therapeutics, 2021, 4, 2100046.	1.6	8
226	Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications. Frontiers in Oncology, 2021, 11, 701777.	1.3	21
227	Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 695325.	1.8	27
228	The efficacy of dendritic cell vaccine for newly diagnosed glioblastoma: A meta-analysis of randomized controlled studies. Neurochirurgie, 2021, 67, 433-438.	0.6	4
229	Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review. International Journal of General Medicine, 2021, Volume 14, 5209-5220.	0.8	4
230	Current Immunotherapeutic Strategies for the Treatment of Glioblastoma. Cancers, 2021, 13, 4548.	1.7	16
231	The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure. Cells, 2021, 10, 2361.	1.8	36
232	The Challenges and Future of Immunotherapy for Gliomas. Cancer Journal (Sudbury, Mass), 2021, 27, 371-378.	1.0	3
233	New Immunotherapeutic Approaches for Glioblastoma. Journal of Immunology Research, 2021, 2021, 1-19.	0.9	7
234	Adoptive cell therapy for glioma. , 2022, , 73-89.		1
235	Targeting the molecular mechanisms of glioma stem cell resistance to chemotherapy. , 2021, , 587-634.		1
237	Prophylactic Dendritic Cell-Based Vaccines Efficiently Inhibit Metastases in Murine Metastatic Melanoma. PLoS ONE, 2015, 10, e0136911.	1.1	27
238	Cell-Based IL-15:IL-15RÎ± Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice. Molecules and Cells, 2019, 42, 869-883.	1.0	9
239	Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling. Aging, 2020, 12, 7112-7128.	1.4	15

#	Article	IF	Citations
240	New extracellular factors in glioblastoma multiforme development: neurotensin, growth differentiation factor-15, sphingosine-1-phosphate and cytomegalovirus infection. Oncotarget, 2018, 9, 7219-7270.	0.8	16
241	A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. Oncotarget, 2018, 9, 21569-21579.	0.8	20
242	Expression of Cancer/Testis Antigens is Correlated with Improved Survival in Glioblastoma. Oncotarget, 2013, 4, 636-646.	0.8	54
243	Cancer Stem Cells and Combination Therapies to Eradicate Them. Current Pharmaceutical Design, 2020, 26, 1994-2008.	0.9	6
244	Diagnosis and New Treatment Modalities for Glioblastoma: Do They Improve Patient Survival?. Current Molecular Medicine, 2016, 16, 447-464.	0.6	7
245	Innovative therapies for malignant brain tumors: the road to a tailored cure. Acta Biomedica, 2020, 91, 5-17.	0.2	21
246	Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials. Acta Naturae, 2017, 9, 27-38.	1.7	8
247	Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged. Cancers, 2021, 13, 32.	1.7	27
248	HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma. Oncology Reports, 2019, 42, 2309-2322.	1.2	14
249	Novel Approaches to Pediatric Cancer: Immunotherapy. AIMS Medical Science, 2015, 2, 104-117.	0.2	1
250	Impact of the immune system and immunotherapy in colorectal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 208-23.	0.6	142
251	In Silico Design of Multi-Epitope ESAT-6:Ag85b:Fcî³2a Fusion Protein as a Novel Candidate for Tuberculosis Vaccine. Archives of Clinical Infectious Diseases, 2020, 15, .	0.1	5
252	Novel Immunotherapeutics for the Treatment of Glioblastoma: The Last Decade of Research. Cureus, 2018, 10, e2130.	0.2	4
253	Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (Review). Experimental and Therapeutic Medicine, 2021, 22, 1408.	0.8	16
254	Prophylactic dendritic cell vaccination in antitumor immune response and tumor growth in a breast cancer mouse model. Research, Society and Development, 2021, 10, e100101320905.	0.0	0
255	Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Frontiers in Immunology, 2021, 12, 721830.	2.2	50
256	Why not change classical treatments for glioblastoma in elderly patients?. World Journal of Experimental Medicine, 2013, 3, 50.	0.9	0
257	Distinctive parameters of action of stem cells and modulatory microenvironmental microcirculation in gliomagenesis. Stem Cell Discovery, 2013, 03, 1-6.	0.5	0

#	Article	IF	Citations
258	General Principles of Immunotherapy for Glioblastoma. , 2016, , 237-246.		1
259	Knockdown of actin-like 8 inhibits cell proliferation by regulating FOXM1, STMN1, PLK1, and BIRC5 in lung adenocarcinoma A549 cells. Translational Cancer Research, 2019, 8, 1975-1984.	0.4	2
260	Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End. Frontiers in Immunology, 2021, 12, 770390.	2.2	44
262	In Silico Model Estimates the Clinical Trial Outcome of Cancer Vaccines. Cells, 2021, 10, 3048.	1.8	4
263	Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials. Acta Naturae, 2017, 9, 27-38.	1.7	5
264	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Advanced Drug Delivery Reviews, 2022, 181, 114033.	6.6	5
265	The Efficacy of Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma: A Meta-analysis of Randomized Controlled Studies. Clinical Neuropharmacology, 2021, 44, 216-221.	0.2	5
266	A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma. Clinical Cancer Research, 2022, 28, 689-696.	3.2	38
267			

#	Article	IF	Citations
277	Emerging Biomarkers for Immunotherapy in Glioblastoma. Cancers, 2022, 14, 1940.	1.7	6
280	Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations. OncoTargets and Therapy, 2022, Volume 15, 437-468.	1.0	11
282	Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence. Journal of Hematology and Oncology, 2022, 15, .	6.9	23
283	Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development. Journal of Big Data, 2022, 9, .	6.9	21
284	Impact of molecular and clinical variables on survival outcome with immunotherapy for glioblastoma patients: A systematic review and metaâ€analysis. CNS Neuroscience and Therapeutics, 2022, 28, 1476-1491.	1.9	5
285	Dendritic cell vaccines for glioblastoma fail to complete clinical translation: Bottlenecks and potential countermeasures. International Immunopharmacology, 2022, 109, 108929.	1.7	12
286	The multifaceted mechanisms of malignant glioblastoma progression and clinical implications. Cancer and Metastasis Reviews, 2022, 41, 871-898.	2.7	8
287	Emerging immune-based technologies for high-grade gliomas. Expert Review of Anticancer Therapy, 2022, 22, 957-980.	1.1	1
288	Advanced Cell Therapies for Glioblastoma. Frontiers in Immunology, 0, 13, .	2.2	7
289	Exosome-based strategies for diagnosis and therapy of glioma cancer. Cancer Cell International, 2022, 22, .	1.8	16
290	A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy (Review). Oncology Reports, 2022, 48, .	1.2	7
291	Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. Vaccines, 2022, 10, 1448.	2.1	3
292	Characterization and Treatment of Spinal Tumors. Intensive Care Research, 2022, 2, 76-95.	0.2	6
293	Interleukin 13 receptor alpha 2 (IL13RÎ±2): Expression, signaling pathways and therapeutic applications in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188802.	3.3	10
294	Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. Frontiers in Oncology, 0, 12, .	1.3	1
295	Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4+ T-cell Responses in Glioblastoma. Clinical Cancer Research, 2022, 28, 5368-5382.	3.2	6
296	Immunotherapeutic Strategies for Glioma Treatment. , 2022, , .		0
297	Peptide antitumor vaccines targeting HER2/neu. , 2022, 21, 22-29.	0.3	0

#	Article	IF	Citations
298	Activated T cell therapy targeting glioblastoma cancer stem cells. Scientific Reports, 2023, 13, .	1.6	0
299	The Role of Cellular Immunity and Adaptive Immunity in Pathophysiology of Brain and Spinal Cord Tumors. Advances in Experimental Medicine and Biology, 2023, , 51-72.	0.8	0
300	Perspective Chapter: Dendritic Cells in The Tumor Microenvironment. , 0, , .		0
301	Next-generation antigen-presenting cell immune therapeutics for gliomas. Journal of Clinical Investigation, 2023, 133, .	3.9	11
302	Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies. Viruses, 2023, 15, 547.	1.5	15
303	Immunotherapy associated central nervous system complications in primary brain tumors. Frontiers in Oncology, 0, 13, .	1.3	2
304	Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies. Frontiers in Immunology, 0, 14, .	2.2	1
305	Personalised therapeutic approaches to glioblastoma: A systematic review. Frontiers in Medicine, 0, 10, .	1.2	4
310	Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma. BioDrugs, 2023, 37, 489-503.	2.2	1
315	Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients. Methods in Cell Biology, 2023, , .	0.5	0